Inactive Instrument

News Immune Therapeutics, Inc. Other OTC

Equities

IMUN

US45252A1079

Summary

Unlock all the news: Be the first to know and act before the market!

Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception	11-30	AQ
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro	11-15	AQ
Biostax Corp. Appoints Craig Suro as a Director	11-15	CI
Biostax Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Biostax Corp. Appoints Mary Clay Caperton to its Board of Directors	11-02	CI
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors	11-02	AQ
Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment	23-10-24	AQ
Immune Therapeutics, Inc. will Change its Name to Biostax Corp	23-10-05	CI
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky	23-09-14	AQ
Immune Therapeutics, Inc. Announces CEO Changes	23-09-13	CI
Immune Therapeutics, Inc. Announces Management Changes	23-09-13	CI
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV	23-08-29	CI
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV	23-08-29	AQ
Immune Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH	23-08-15	AQ
Immune Therapeutics, Inc. Announces the Fdas Acceptance of Three Investigational New Drug Applications Transfers for Jkb-122 for the Treatment of Nash, Nafld and Aih	23-08-15	CI
Biostax Launches Growth Funding Round to Revitalize Affordable Healthcare	23-05-30	PR
Biostax Corp. announced that it expects to receive $12 million in funding from DealBox, Inc	23-05-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immune Therapeutics, Inc. Other OTC

Equities

IMUN

US45252A1079

Summary

Filters